Sort   by:  
 Page size 
UnknownA Multisite Preregistered Paradigmatic Test of the Ego-Depletion Effect.
We conducted a preregistered multilaboratory project (k = 36; N = 3,531) to assess the size and robustness of ego-depletion effects using a novel replication method, termed the paradigmatic replication approach. Each laboratory implemented one of two procedures that was intended...
S-EPMC12422598 | biostudies-literature
UnknownTherapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.

Background

Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19.

Methods

In an open-label, ad...
S-EPMC8362592 | biostudies-literature
UnknownEmpagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Background

Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19.

Methods

In the randomised, cont...
S-EPMC10957483 | biostudies-literature
UnknownHigher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.

Background

Low dose corticosteroids (e.g., 6 mg dexamethasone) have been shown to reduce mortality for hypoxic COVID-19 patients. We have previously reported that higher dose corticosteroids cause harm in patients with clinical hypoxia but not receiving ventilatory support (the combination o...
S-EPMC11872607 | biostudies-literature
UnknownAzithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Background

Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.

Methods

In this randomised, controlled, open-label, adaptive...
S-EPMC7884931 | biostudies-literature
UnknownInterleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.

Background

The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.

Methods

We evaluated tocilizumab and sarilumab in an ongoing international, multifactorial, adaptive platform trial. Adult patients with Covid-...
S-EPMC7953461 | biostudies-literature
UnknownPrediction of disability-free survival in healthy older people.
Prolonging survival in good health is a fundamental societal goal. However, the leading determinants of disability-free survival in healthy older people have not been well established. Data from ASPREE, a bi-national placebo-controlled trial of aspirin with 4.7 years median follow-up, was analysed. ...
S-EPMC9213595 | biostudies-literature
UnknownEffect of Aspirin on Disability-free Survival in the Healthy Elderly.

Background

Information on the use of aspirin to increase healthy independent life span in older persons is limited. Whether 5 years of daily low-dose aspirin therapy would extend disability-free life in healthy seniors is unclear.

Methods

From 2010 through 2014, we enrolled community-...
S-EPMC6426126 | biostudies-literature
UnknownEffect of Aspirin on All-Cause Mortality in the Healthy Elderly.

Background

In the primary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, now published in the Journal, we report that the daily use of aspirin did not provide a benefit with regard to the primary end point of disability-free survival among older adults. A numerical...
S-EPMC6433466 | biostudies-literature
UnknownEffect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.

Background

Aspirin is a well-established therapy for the secondary prevention of cardiovascular events. However, its role in the primary prevention of cardiovascular disease is unclear, especially in older persons, who have an increased risk.

Methods

From 2010 through 2014, we enrolle...
S-EPMC6289056 | biostudies-literature
Sort   by:  
 Page size